Keros Therapeutics, Inc. (KROS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 18,168 | 211,246 | 388 | 37 |
| Research and development | 43,503 | 48,709 | 49,225 | 40,515 |
| General and administrative | 14,482 | 10,497 | 9,820 | 9,961 |
| Total operating expenses | 57,985 | 59,206 | 59,045 | 50,476 |
| Income (loss) from operations | -39,817 | 152,040 | -58,657 | -50,439 |
| Other expense, net | -221 | -338 | -92 | -196 |
| Dividend income | 7,120 | 6,792 | 5,793 | 5,378 |
| Total other income, net | 6,899 | 6,454 | 5,701 | 5,182 |
| Income (loss) before income taxes | -32,918 | 158,494 | - | - |
| Income tax (provision) benefit | -2,222 | 10,043 | - | - |
| Net income (loss) | -30,696 | 148,451 | -52,956 | -45,257 |
| Net income (loss) per share of common stock - basic (in usd per share) | -0.76 | 3.66 | -1.41 | -1.25 |
| Net income (loss) per share of common stock - diluted (in usd per share) | -0.76 | 3.62 | -1.41 | -1.25 |
| Weighted average shares of common stock outstanding - basic (in shares) | 40,612,907 | 40,559,355 | 37,590,727 | 36,103,187 |
| Weighted average shares of common stock outstanding - diluted (in shares) | 40,612,907 | 41,021,325 | 37,590,727 | 36,103,187 |